Stocks · News reference
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 49.11 percent increase over losses of $(1.12) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in
Filed: 2026-09-28 AccNo: 0001178253-26-000037 Size: 210 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served